Answers are grounded in this paper and cite their sources.
¹⁸F-FDG PET/CT has some limitations in the evaluation of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL), an indolent B-cell lymphoma that primarily involves the bone marrow. Because there is a high level of chemokine receptor 4 expression in the B cells of WM/LPL patients, we performed a prospective cohort study to evaluate the performance of ⁶⁸Ga-pentixafor, which targets chemokine receptor 4 in WM/LPL, and to compare it with the performance of ¹⁸F-FDG. Methods: Seventeen patients with WM/LPL were recruited. All patients underwent both ⁶⁸Ga-pentixafor PET/CT and ¹⁸F-FDG PET/CT. A positive PET/CT result was defined as the presence of focal lesions with positive PET results or diffuse bone marrow patterns (uptake > liver). The rates of positive results for PET/CT scans of bone marrow, lymph nodes, and other extramedullary involvement were statistically compared. Results:⁶⁸Ga-pentixafor PET/CT had a higher rate of positive results than ¹⁸F-FDG PET/CT (100% vs. 58.8%; P = 0.023) in the recruited WM/LPL patients. The sensitivities of ⁶⁸Ga-pentixafor PET/CT and ¹⁸F-FDG PET/CT for detecting bone marrow involvement were 94.1% and 58.8%, respectively (P = 0.077). In terms of detecting lymph node involvement, ⁶⁸Ga-pentixafor PET/CT had a significantly higher rate of positive results than ¹⁸F-FDG PET/CT (76.5% vs. 11.8%; P = 0.003). In addition, ⁶⁸Ga-pentixafor detected more paramedullary and central nervous system involvement than ¹⁸F-FDG. Conclusion:⁶⁸Ga-pentixafor might be a promising imaging agent for the assessment of WM/LPL.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: